Cargando…
Employing a Gain-of-Function Factor IX Variant R338L to Advance the Efficacy and Safety of Hemophilia B Human Gene Therapy: Preclinical Evaluation Supporting an Ongoing Adeno-Associated Virus Clinical Trial
Vector capsid dose-dependent inflammation of transduced liver has limited the ability of adeno-associated virus (AAV) factor IX (FIX) gene therapy vectors to reliably convert severe to mild hemophilia B in human clinical trials. These trials also identified the need to understand AAV neutralizing an...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326268/ https://www.ncbi.nlm.nih.gov/pubmed/25419787 http://dx.doi.org/10.1089/hum.2014.106 |
_version_ | 1782356899571695616 |
---|---|
author | Monahan, Paul E. Sun, Junjiang Gui, Tong Hu, Genlin Hannah, William B. Wichlan, David G. Wu, Zhijian Grieger, Joshua C. Li, Chengwen Suwanmanee, Thipparat Stafford, Darrel W. Booth, Carmen J. Samulski, Jade J. Kafri, Tal McPhee, Scott W.J. Samulski, R. Jude |
author_facet | Monahan, Paul E. Sun, Junjiang Gui, Tong Hu, Genlin Hannah, William B. Wichlan, David G. Wu, Zhijian Grieger, Joshua C. Li, Chengwen Suwanmanee, Thipparat Stafford, Darrel W. Booth, Carmen J. Samulski, Jade J. Kafri, Tal McPhee, Scott W.J. Samulski, R. Jude |
author_sort | Monahan, Paul E. |
collection | PubMed |
description | Vector capsid dose-dependent inflammation of transduced liver has limited the ability of adeno-associated virus (AAV) factor IX (FIX) gene therapy vectors to reliably convert severe to mild hemophilia B in human clinical trials. These trials also identified the need to understand AAV neutralizing antibodies and empty AAV capsids regarding their impact on clinical success. To address these safety concerns, we have used a scalable manufacturing process to produce GMP-grade AAV8 expressing the FIXR338L gain-of-function variant with minimal (<10%) empty capsid and have performed comprehensive dose–response, biodistribution, and safety evaluations in clinically relevant hemophilia models. The scAAV8.FIXR338L vector produced greater than 6-fold increased FIX specific activity compared with wild-type FIX and demonstrated linear dose responses from doses that produced 2–500% FIX activity, associated with dose-dependent hemostasis in a tail transection bleeding challenge. More importantly, using a bleeding model that closely mimics the clinical morbidity of hemophilic arthropathy, mice that received the scAAV8.FIXR338L vector developed minimal histopathological findings of synovitis after hemarthrosis, when compared with mice that received identical doses of wild-type FIX vector. Hemostatically normal mice (n=20) and hemophilic mice (n=88) developed no FIX antibodies after peripheral intravenous vector delivery. No CD8(+) T cell liver infiltrates were observed, despite the marked tropism of scAAV8.FIXR338L for the liver in a comprehensive biodistribution evaluation (n=60 animals). With respect to the role of empty capsids, we demonstrated that in vivo FIXR338L expression was not influenced by the presence of empty AAV particles, either in the presence or absence of various titers of AAV8-neutralizing antibodies. Necropsy of FIX(–/–) mice 8–10 months after vector delivery revealed no microvascular or macrovascular thrombosis in mice expressing FIXR338L (plasma FIX activity, 100–500%). These preclinical studies demonstrate a safety:efficacy profile supporting an ongoing phase 1/2 human clinical trial of the scAAV8.FIXR338L vector (designated BAX335). |
format | Online Article Text |
id | pubmed-4326268 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Mary Ann Liebert, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-43262682015-02-24 Employing a Gain-of-Function Factor IX Variant R338L to Advance the Efficacy and Safety of Hemophilia B Human Gene Therapy: Preclinical Evaluation Supporting an Ongoing Adeno-Associated Virus Clinical Trial Monahan, Paul E. Sun, Junjiang Gui, Tong Hu, Genlin Hannah, William B. Wichlan, David G. Wu, Zhijian Grieger, Joshua C. Li, Chengwen Suwanmanee, Thipparat Stafford, Darrel W. Booth, Carmen J. Samulski, Jade J. Kafri, Tal McPhee, Scott W.J. Samulski, R. Jude Hum Gene Ther Research Articles Vector capsid dose-dependent inflammation of transduced liver has limited the ability of adeno-associated virus (AAV) factor IX (FIX) gene therapy vectors to reliably convert severe to mild hemophilia B in human clinical trials. These trials also identified the need to understand AAV neutralizing antibodies and empty AAV capsids regarding their impact on clinical success. To address these safety concerns, we have used a scalable manufacturing process to produce GMP-grade AAV8 expressing the FIXR338L gain-of-function variant with minimal (<10%) empty capsid and have performed comprehensive dose–response, biodistribution, and safety evaluations in clinically relevant hemophilia models. The scAAV8.FIXR338L vector produced greater than 6-fold increased FIX specific activity compared with wild-type FIX and demonstrated linear dose responses from doses that produced 2–500% FIX activity, associated with dose-dependent hemostasis in a tail transection bleeding challenge. More importantly, using a bleeding model that closely mimics the clinical morbidity of hemophilic arthropathy, mice that received the scAAV8.FIXR338L vector developed minimal histopathological findings of synovitis after hemarthrosis, when compared with mice that received identical doses of wild-type FIX vector. Hemostatically normal mice (n=20) and hemophilic mice (n=88) developed no FIX antibodies after peripheral intravenous vector delivery. No CD8(+) T cell liver infiltrates were observed, despite the marked tropism of scAAV8.FIXR338L for the liver in a comprehensive biodistribution evaluation (n=60 animals). With respect to the role of empty capsids, we demonstrated that in vivo FIXR338L expression was not influenced by the presence of empty AAV particles, either in the presence or absence of various titers of AAV8-neutralizing antibodies. Necropsy of FIX(–/–) mice 8–10 months after vector delivery revealed no microvascular or macrovascular thrombosis in mice expressing FIXR338L (plasma FIX activity, 100–500%). These preclinical studies demonstrate a safety:efficacy profile supporting an ongoing phase 1/2 human clinical trial of the scAAV8.FIXR338L vector (designated BAX335). Mary Ann Liebert, Inc. 2015-02-01 2014-11-24 /pmc/articles/PMC4326268/ /pubmed/25419787 http://dx.doi.org/10.1089/hum.2014.106 Text en Copyright 2015, Mary Ann Liebert, Inc. © Paul E. Monahan et al. 2015; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License Attribution-Non-Commercial Share Alike (http://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Research Articles Monahan, Paul E. Sun, Junjiang Gui, Tong Hu, Genlin Hannah, William B. Wichlan, David G. Wu, Zhijian Grieger, Joshua C. Li, Chengwen Suwanmanee, Thipparat Stafford, Darrel W. Booth, Carmen J. Samulski, Jade J. Kafri, Tal McPhee, Scott W.J. Samulski, R. Jude Employing a Gain-of-Function Factor IX Variant R338L to Advance the Efficacy and Safety of Hemophilia B Human Gene Therapy: Preclinical Evaluation Supporting an Ongoing Adeno-Associated Virus Clinical Trial |
title | Employing a Gain-of-Function Factor IX Variant R338L to Advance the Efficacy and Safety of Hemophilia B Human Gene Therapy: Preclinical Evaluation Supporting an Ongoing Adeno-Associated Virus Clinical Trial |
title_full | Employing a Gain-of-Function Factor IX Variant R338L to Advance the Efficacy and Safety of Hemophilia B Human Gene Therapy: Preclinical Evaluation Supporting an Ongoing Adeno-Associated Virus Clinical Trial |
title_fullStr | Employing a Gain-of-Function Factor IX Variant R338L to Advance the Efficacy and Safety of Hemophilia B Human Gene Therapy: Preclinical Evaluation Supporting an Ongoing Adeno-Associated Virus Clinical Trial |
title_full_unstemmed | Employing a Gain-of-Function Factor IX Variant R338L to Advance the Efficacy and Safety of Hemophilia B Human Gene Therapy: Preclinical Evaluation Supporting an Ongoing Adeno-Associated Virus Clinical Trial |
title_short | Employing a Gain-of-Function Factor IX Variant R338L to Advance the Efficacy and Safety of Hemophilia B Human Gene Therapy: Preclinical Evaluation Supporting an Ongoing Adeno-Associated Virus Clinical Trial |
title_sort | employing a gain-of-function factor ix variant r338l to advance the efficacy and safety of hemophilia b human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326268/ https://www.ncbi.nlm.nih.gov/pubmed/25419787 http://dx.doi.org/10.1089/hum.2014.106 |
work_keys_str_mv | AT monahanpaule employingagainoffunctionfactorixvariantr338ltoadvancetheefficacyandsafetyofhemophiliabhumangenetherapypreclinicalevaluationsupportinganongoingadenoassociatedvirusclinicaltrial AT sunjunjiang employingagainoffunctionfactorixvariantr338ltoadvancetheefficacyandsafetyofhemophiliabhumangenetherapypreclinicalevaluationsupportinganongoingadenoassociatedvirusclinicaltrial AT guitong employingagainoffunctionfactorixvariantr338ltoadvancetheefficacyandsafetyofhemophiliabhumangenetherapypreclinicalevaluationsupportinganongoingadenoassociatedvirusclinicaltrial AT hugenlin employingagainoffunctionfactorixvariantr338ltoadvancetheefficacyandsafetyofhemophiliabhumangenetherapypreclinicalevaluationsupportinganongoingadenoassociatedvirusclinicaltrial AT hannahwilliamb employingagainoffunctionfactorixvariantr338ltoadvancetheefficacyandsafetyofhemophiliabhumangenetherapypreclinicalevaluationsupportinganongoingadenoassociatedvirusclinicaltrial AT wichlandavidg employingagainoffunctionfactorixvariantr338ltoadvancetheefficacyandsafetyofhemophiliabhumangenetherapypreclinicalevaluationsupportinganongoingadenoassociatedvirusclinicaltrial AT wuzhijian employingagainoffunctionfactorixvariantr338ltoadvancetheefficacyandsafetyofhemophiliabhumangenetherapypreclinicalevaluationsupportinganongoingadenoassociatedvirusclinicaltrial AT griegerjoshuac employingagainoffunctionfactorixvariantr338ltoadvancetheefficacyandsafetyofhemophiliabhumangenetherapypreclinicalevaluationsupportinganongoingadenoassociatedvirusclinicaltrial AT lichengwen employingagainoffunctionfactorixvariantr338ltoadvancetheefficacyandsafetyofhemophiliabhumangenetherapypreclinicalevaluationsupportinganongoingadenoassociatedvirusclinicaltrial AT suwanmaneethipparat employingagainoffunctionfactorixvariantr338ltoadvancetheefficacyandsafetyofhemophiliabhumangenetherapypreclinicalevaluationsupportinganongoingadenoassociatedvirusclinicaltrial AT stafforddarrelw employingagainoffunctionfactorixvariantr338ltoadvancetheefficacyandsafetyofhemophiliabhumangenetherapypreclinicalevaluationsupportinganongoingadenoassociatedvirusclinicaltrial AT boothcarmenj employingagainoffunctionfactorixvariantr338ltoadvancetheefficacyandsafetyofhemophiliabhumangenetherapypreclinicalevaluationsupportinganongoingadenoassociatedvirusclinicaltrial AT samulskijadej employingagainoffunctionfactorixvariantr338ltoadvancetheefficacyandsafetyofhemophiliabhumangenetherapypreclinicalevaluationsupportinganongoingadenoassociatedvirusclinicaltrial AT kafrital employingagainoffunctionfactorixvariantr338ltoadvancetheefficacyandsafetyofhemophiliabhumangenetherapypreclinicalevaluationsupportinganongoingadenoassociatedvirusclinicaltrial AT mcpheescottwj employingagainoffunctionfactorixvariantr338ltoadvancetheefficacyandsafetyofhemophiliabhumangenetherapypreclinicalevaluationsupportinganongoingadenoassociatedvirusclinicaltrial AT samulskirjude employingagainoffunctionfactorixvariantr338ltoadvancetheefficacyandsafetyofhemophiliabhumangenetherapypreclinicalevaluationsupportinganongoingadenoassociatedvirusclinicaltrial |